Because the main function of EML4-ALK in NSCLC cells is kinase activity, the development of anticancer agents for EML4-ALK has focused on inhibition of the catalytic function of the TK domain [32,33,34,35,36,37,38,39]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.